Therapeutic category of drugs in Japan [BR:br08301]
2 Agents affecting individual organs
26 Epidermides
269 Miscellaneous
2699 Others
D11046 Delgocitinib (JAN/USAN)
Drug groups [BR:br08330]
Anti-inflammatory
DG01985 Disease modifying anti-rheumatic drug (DMARD)
DG02020 JAK inhibitor
D11046 Delgocitinib
Drug classes [BR:br08332]
Immunological agent
DG02020 JAK inhibitor
D11046 Delgocitinib
Antirheumatic agent
DG01985 Disease modifying anti-rheumatic drug (DMARD)
D11046 Delgocitinib
Target-based classification of drugs [BR:br08310]
Protein kinases
Non-receptor tyrosine kinases
JAK family
JAK1
D11046 Delgocitinib (JAN/USAN) <JP>
JAK2
D11046 Delgocitinib (JAN/USAN) <JP>
JAK3
D11046 Delgocitinib (JAN/USAN) <JP>
TYK2
D11046 Delgocitinib (JAN/USAN) <JP>
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D11046
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11046
Other DBs
CAS:
1263774-59-9
PubChem:
363669759
ChEBI:
167600
PDB-CCD:
FHX[PDBj]
KCF data
ATOM 23
1 C8y C 17.0067 -13.3562
2 C8y C 17.0067 -11.9505
3 N5x N 18.2015 -11.2476
4 C8x C 19.4667 -11.9505
5 N5x N 19.4667 -13.3562
6 C8y C 18.2015 -14.0591
7 C8x C 15.6712 -13.7779
8 C8x C 14.8278 -12.6533
9 N4x N 15.6712 -11.5287
10 N1y N 18.2015 -15.4648
11 C1x C 19.3262 -16.3082
12 C1x C 18.9044 -17.5734
13 C1z C 17.4987 -17.5734
14 C1x C 17.0769 -16.3082
15 C1y C 16.0930 -17.7842
16 C1x C 16.3741 -19.1900
17 N1y N 17.7798 -18.9791
18 C1a C 14.9425 -16.9764
19 C5a C 18.9332 -19.7847
20 C1b C 20.1445 -19.0902
21 O5a O 18.9282 -21.1579
22 C3b C 21.2664 -19.7833
23 N3a N 22.4807 -20.4844
BOND 26
1 1 2 2
2 2 3 1
3 3 4 2
4 4 5 1
5 5 6 2
6 1 6 1
7 1 7 1
8 7 8 2
9 8 9 1
10 2 9 1
11 6 10 1
12 10 11 1
13 11 12 1
14 13 12 1 #Up
15 13 14 1 #Down
16 10 14 1
17 13 15 1
18 15 16 1
19 16 17 1
20 17 13 1
21 15 18 1
22 17 19 1
23 19 20 1
24 19 21 2
25 20 22 1
26 22 23 3